280 related articles for article (PubMed ID: 26394025)
1. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications.
Kodela R; Chattopadhyay M; Velázquez-Martínez CA; Kashfi K
Biochem Pharmacol; 2015 Dec; 98(4):564-72. PubMed ID: 26394025
[TBL] [Abstract][Full Text] [Related]
2. NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties.
Kashfi K; Chattopadhyay M; Kodela R
Redox Biol; 2015 Dec; 6():287-296. PubMed ID: 26298203
[TBL] [Abstract][Full Text] [Related]
3. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model.
Chattopadhyay M; Kodela R; Olson KR; Kashfi K
Biochem Biophys Res Commun; 2012 Mar; 419(3):523-8. PubMed ID: 22366248
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and anti-cancer potential of the positional isomers of NOSH-aspirin (NBS-1120) a dual nitric oxide and hydrogen sulfide releasing hybrid.
Vannini F; MacKessack-Leitch AC; Eschbach EK; Chattopadhyay M; Kodela R; Kashfi K
Bioorg Med Chem Lett; 2015 Oct; 25(20):4677-82. PubMed ID: 26323873
[TBL] [Abstract][Full Text] [Related]
5. Utility Of Nitric Oxide And Hydrogen Sulfide-Releasing Chimeras As Anticancer Agents.
Kashfi K
Redox Biol; 2015 Aug; 5():420. PubMed ID: 28162289
[TBL] [Abstract][Full Text] [Related]
6. Comparison between 3-Nitrooxyphenyl acetylsalicylate (NO-ASA) and O2-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (NONO-ASA) as safe anti-inflammatory, analgesic, antipyretic, antioxidant prodrugs.
Chattopadhyay M; Velazquez CA; Pruski A; Nia KV; Abdellatif KR; Keefer LK; Kashfi K
J Pharmacol Exp Ther; 2010 Nov; 335(2):443-50. PubMed ID: 20679133
[TBL] [Abstract][Full Text] [Related]
7. NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-κB, iNOS, caspase-3 and ROS.
Chattopadhyay M; Kodela R; Santiago G; Le TTC; Nath N; Kashfi K
Biochem Pharmacol; 2020 Jun; 176():113857. PubMed ID: 32061771
[TBL] [Abstract][Full Text] [Related]
8. NOSH-aspirin (NBS-1120), a novel nitric oxide and hydrogen sulfide releasing hybrid, attenuates neuroinflammation induced by microglial and astrocytic activation: a new candidate for treatment of neurodegenerative disorders.
Lee M; McGeer E; Kodela R; Kashfi K; McGeer PL
Glia; 2013 Oct; 61(10):1724-34. PubMed ID: 23918470
[TBL] [Abstract][Full Text] [Related]
9. Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling.
Vannini F; Chattopadhyay M; Kodela R; Rao PPN; Kashfi K
Redox Biol; 2015 Dec; 6():318-325. PubMed ID: 26319435
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal anti-inflammatory drugs and gastric mucosal responses.
Takeuchi K; Suzuki K; Yamamoto H; Araki H; Mizoguchi H; Ukawa H
J Physiol Pharmacol; 1998 Dec; 49(4):501-13. PubMed ID: 10069692
[TBL] [Abstract][Full Text] [Related]
11. NOSH-aspirin (NBS-1120), a dual nitric oxide and hydrogen sulfide-releasing hybrid, reduces inflammatory pain.
Fonseca MD; Cunha FQ; Kashfi K; Cunha TM
Pharmacol Res Perspect; 2015 Jun; 3(3):e00133. PubMed ID: 26236481
[TBL] [Abstract][Full Text] [Related]
12. Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative.
Wallace JL; McKnight W; Del Soldato P; Baydoun AR; Cirino G
J Clin Invest; 1995 Dec; 96(6):2711-8. PubMed ID: 8675638
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide (NO)-releasing aspirin and (NO) donors in protection of gastric mucosa against stress.
S Kwiecien S; Pawlik MW; Brzozowski T; Konturek PC; Sliwowski Z; Pawlik WW; Konturek SJ
J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():103-15. PubMed ID: 18812632
[TBL] [Abstract][Full Text] [Related]
14. Effects of conventional and hydrogen sulfide-releasing non-steroidal anti-inflammatory drugs in rats with stress-induced and epinephrine-induced gastric damage.
Fomenko I; Sklyarov A; Bondarchuk T; Biletska L; Panasyuk N; Wallace JL
Stress; 2014 Dec; 17(6):528-37. PubMed ID: 25238023
[TBL] [Abstract][Full Text] [Related]
15. New nitric oxide or hydrogen sulfide releasing aspirins.
Lazzarato L; Chegaev K; Marini E; Rolando B; Borretto E; Guglielmo S; Joseph S; Di Stilo A; Fruttero R; Gasco A
J Med Chem; 2011 Aug; 54(15):5478-84. PubMed ID: 21688846
[TBL] [Abstract][Full Text] [Related]
16. NOSH-Aspirin Inhibits Colon Cancer Cell Growth: Effects Of Positional Isomerism.
Vannini F; Kodela R; Chattopadhyay M; Kashfi K
Redox Biol; 2015 Aug; 5():421. PubMed ID: 28162291
[TBL] [Abstract][Full Text] [Related]
17. NO-releasing NSAIDs suppress NF-κB signaling in vitro and in vivo through S-nitrosylation.
Chattopadhyay M; Goswami S; Rodes DB; Kodela R; Velazquez CA; Boring D; Crowell JA; Kashfi K
Cancer Lett; 2010 Dec; 298(2):204-11. PubMed ID: 20674154
[TBL] [Abstract][Full Text] [Related]
18. Hydrogen sulfide-releasing aspirin derivative ACS14 exerts strong antithrombotic effects in vitro and in vivo.
Pircher J; Fochler F; Czermak T; Mannell H; Kraemer BF; Wörnle M; Sparatore A; Del Soldato P; Pohl U; Krötz F
Arterioscler Thromb Vasc Biol; 2012 Dec; 32(12):2884-91. PubMed ID: 23023375
[TBL] [Abstract][Full Text] [Related]
19. Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation.
Wallace JL; Zamuner SR; McKnight W; Dicay M; Mencarelli A; del Soldato P; Fiorucci S
Am J Physiol Gastrointest Liver Physiol; 2004 Jan; 286(1):G76-81. PubMed ID: 14665439
[TBL] [Abstract][Full Text] [Related]
20. Exploring the Potential of Nitric Oxide and Hydrogen Sulfide (NOSH)-Releasing Synthetic Compounds as Novel Priming Agents against Drought Stress in
Antoniou C; Xenofontos R; Chatzimichail G; Christou A; Kashfi K; Fotopoulos V
Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31936819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
